# Study of Ixekizumab in Healthy Participants

> **NCT03848403** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ixekizumab

## Key facts

- **NCT ID:** NCT03848403
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-29
- **Primary completion:** 2019-07-18
- **Final completion:** 2019-07-18
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** At the protocol-specified interim analysis, the sponsor decided to stop the trial.
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03848403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03848403, "Study of Ixekizumab in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03848403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*